Akanocure Pharmaceuticals Inc., headquartered in the Purdue Research Park of West Lafayette, has begun offering packets of chemical building blocks that will enable the creation of a rare class of compounds produced by plants, marine life and other small life forms. These compounds show promise in stopping the growth of bacteria, viruses, fungi, parasites and cancer tumor cells.
The ability to produce the compounds on a large scale could lead to new drugs to fight cancer and other diseases.
According to Sherine Abdelmawla, Akanocure’s co-founder and CEO, these compounds, called polyproprionate polyketides, can’t be harvested from their natural sources since they are produced in such small quantities. They also can’t be made from scratch synthetically due to their complex structure and the absence of an efficient way to do so on a large scale.
“Akanocure’s chemical stereotetrad building blocks will ease the synthesis of such compounds and may increase their number in the drug development pipelines,” Abdelmawla said. “These compounds would represent a treasure trove of potential drugs if they can be made on a large scale. That translates to more options for patients.”
Purdue University researchers led by Philip Fuchs, the emeritus R. B. Wetherill Professor of Organic Chemistry, helped develop the technology that allows large-scale synthesis of complex natural products. Fuchs is a co-founder of Akanocure along with Abdelmawla and Mohammad Noshi.
Abdelmawla has more than 10 years of experience working in academia and in biotechnology and pharmaceutical industries to develop HCV inhibitors, nucleic acid-based cancer therapeutics and cancer diagnostics.
Noshi has more than 10 years of experience within academic and industrial settings developing chemistry methodologies, synthesis of anti-cancer natural products, complex alkaloids synthesis, diagnostic agents for image-guided surgery in cancer and potential drug candidates for Alzheimer’s disease and prostate cancer.
“We want to use our line of building blocks to produce a number of pipeline candidates in the future to treat unmet needs in the fight against cancer,” Noshi said. “Akanocure also strives to add more building blocks to its library in the future to enable the synthesis of more biologically relevant compounds for the scientific community.”
Akanocure Pharmaceuticals was chosen to participate in the FOUNDER.org Class of 2016. It received $100,000 from the program in 2015. It also received a combined $80,000 from the Elevate Purdue Foundry Fund in 2015 and 2016.
Akanocure Pharmaceuticals has licensed the technology through the Purdue Research Foundation Office of Technology Commercialization.
A link to Akanocure’s new product line is available here. More information about Akanocure Pharmaceuticals is available at www.akanocure.com.